Physician profile
Laura E Meyer
NPI 1972582971
$1,101.44
in general payments reported to CMS, 2019-2025
32 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $159 · 2023: $188 · 2024: $263 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $88.38 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $79.68 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $69.94 | 2024-2025 | Lumryz |
| Ucb, INC. | $58.44 | 2025 | Nayzilam, Zilbrysq, Fintepla |
| Harmony Biosciences LLC | $55.27 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $54.80 | 2021-2022 | |
| Eisai INC. | $53.80 | 2023-2025 | |
| Pfizer INC. | $48.97 | 2023-2025 | |
| Emd Serono, INC. | $43.37 | 2022-2024 | |
| Amgen INC. | $42.19 | 2023-2025 | Aimovig, Uplizna |
| Astellas Pharma US INC | $38.96 | 2023 | Veozah |
| Merz Pharmaceuticals, LLC | $37.79 | 2024 | Xeomin |
| Boston Scientific Corporation | $36.13 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $32.22 | 2024-2025 | |
| Biogen, INC. | $29.27 | 2025 | Vumerity, Tysabri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.74 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $28.64 | 2022 | |
| Lundbeck LLC | $25.40 | 2021 | |
| Corium, LLC | $24.31 | 2022-2023 | Adlarity |
| Hospira, INC. | $23.90 | 2024 | |
| Abbott Laboratories | $23.64 | 2025 | Infinity |
| Catalyst Pharmaceuticals, INC. | $22.95 | 2024 | |
| Tanabe Pharma America, INC. | $19.85 | 2023 | |
| Cala Health, INC. | $17.58 | 2023 | Cala Kiq, Cala Trio |
| Xeris Pharmaceuticals, INC. | $16.88 | 2025 | Keveyis |
| Allergan, INC. | $15.96 | 2022 | |
| Genentech USA, INC. | $15.89 | 2021 | |
| Grifols USA, LLC | $15.40 | 2022 | |
| Ge Healthcare | $15.03 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $13.62 | 2025 | Wainua |
| Celgene Corporation | $12.93 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.